Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?

Hum Psychopharmacol. 2005 Apr;20(3):203-5. doi: 10.1002/hup.682.

Abstract

This is a report on a case series of five patients with psychosis in Parkinson's disease who were treated successfully with an intramuscular injection of ziprasidone (10-20 mg) for acute agitation. No deterioration of motor function or other clinically relevant side effects were seen.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Electrocardiography
  • Emergency Medical Services
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / psychology
  • Piperazines / administration & dosage
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Psychiatric Status Rating Scales
  • Psychomotor Agitation / drug therapy
  • Psychomotor Agitation / etiology
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / etiology*
  • Psychotic Disorders / psychology
  • Thiazoles / administration & dosage
  • Thiazoles / adverse effects
  • Thiazoles / therapeutic use*

Substances

  • Antiparkinson Agents
  • Antipsychotic Agents
  • Piperazines
  • Thiazoles
  • ziprasidone